NCT00869284已完成2 期
Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas
French Innovative Leukemia Organisation2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 1994年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
- 试验地点
- 2
- 主要终点
- Complete response
研究概览
简要总结
Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.
详细描述
High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral blood stem cell support Patients were aged from 15 to 60 years
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients aged from 15 to 60 years
- •previously untreated
- •histologically proven aggressive NHL
- •high aa-IPI (equal to 3)
- •proper underlying organ function
排除标准
- •transformed low-grade, lymphoblastic, mantle-cell, or Burkitt's lymphoma
结局指标
主要结局
Complete response
时间窗: end of treatment
次要结局
- overall survival disease free survival(10 years after treatment)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
EHR-embedded OCDT in Breast or GI CancerOral Cancer Directed TherapyBreast CancerGastrointestinal CancerOral ChemotherapyNCT03858712Dana-Farber Cancer Institute100
已完成
2 期
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-DiabetesNonalcoholic Steatohepatitis (NASH)Type 2 DiabetesNCT05623189HighTide Therapeutics (Hong Kong) Limited218
已完成
2 期
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaLymphoma, FollicularLymphoma, Small LymphocyticNCT00081809Agenus Inc.35
已完成
3 期
Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisRelapsing Multiple SclerosisNCT02047734Celgene1,320
已完成
2 期
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT01031225Synta Pharmaceuticals Corp.113